Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD

Overview

Peripheral muscle mass and strength are relevant indicators of COPD survival. Current guidelines recommend to assess muscle strength only in muscle wasted patients. However, a recent study reported quadriceps weakness without muscle wasting (Menon, M et al. Resp. Res.2012, 13:119). Thus, these guidelines raise the risk to miss out some weak patients. In clinical settings, fat-free-mass index (FFMI) is indicated as a simple index to assess muscle wasting. We aimed at determining the prevalence of patients entering in pulmonary rehabilitation (PR) a priori not eligible for muscle strength evaluation given the lack of muscle wasting clinical signs.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: March 2014

Clinical Trial Outcome Measures

Primary Measures

  • Muscle wasting in COPD patient
    • Time Frame: baseline

Secondary Measures

  • Muscle weakness in COPD patient
    • Time Frame: baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who have got FFMI (bioimpedance) – Patients who have done quadriceps muscle strenght evaluation Exclusion Criteria:

  • Patients without FFMI – Patients without quadriceps muscle strenght

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • 5 Santé
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.